SYNERGISTIC ANTITUMOR INTERACTIONS BETWEEN PANOBINOSTAT AND CONVENTIONAL CHEMOTHERAPY DRUGS IN HIGH-RISK NEUROBLASTOMA

被引：0
|
作者：
Wang, G. [1 ]
Jolly, P. [2 ]
Taub, J. [1 ]
Ge, Y. [2 ]
Wang, Z. [1 ]
机构：
[1] Wayne State Univ, Childrens Hosp Michigan, Detroit, MI USA
[2] Wayne State Univ, Karmanos Canc Ctr, Detroit, MI USA
来源：
PEDIATRIC BLOOD & CANCER | 2013年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：120 / 121
页数：2
相关论文
共 50 条
  • [1] SYNERGISTIC ANTITUMOR INTERACTIONS BETWEEN MK-1775 AND PANOBINOSTAT IN HIGH-RISK NEUROBLASTOMA CELLS
    Hanmod, S.
    Wang, G.
    Edwards, H.
    Buck, S.
    Ge, Y.
    Taub, J.
    Wang, Z.
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S330 - S330
  • [2] Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer
    Wang, Guan
    Niu, Xiaojia
    Zhang, Wenbo
    Caldwell, J. Timothy
    Edwards, Holly
    Chen, Wei
    Taub, Jeffrey W.
    Zhao, Lijing
    Ge, Yubin
    CANCER LETTERS, 2015, 356 (02) : 656 - 668
  • [3] CONVENTIONAL CHEMOTHERAPY OF HIGH-RISK TESTICULAR CANCER
    CHEVREAU, C
    PATHOLOGIE BIOLOGIE, 1994, 42 (10): : 992 - 993
  • [4] P-Glycoprotein is a resistance mechanism for conventional induction chemotherapy but not ALK inhibitors in high-risk neuroblastoma
    Atkinson, Caroline
    Tactacan, Carole
    Kamili, Alvin
    Saletta, Federica
    Gana, Christine
    Eden, Georgina
    Mayoh, Chelsea
    Lock, Richard
    Norris, Murray
    Haber, Michelle
    Gifford, Andrew
    Trahair, Toby
    Fletcher, Jamie
    CANCER RESEARCH, 2020, 80 (14) : 61 - 61
  • [5] Dinutuxumab Beta Plus Conventional Chemotherapy for Relapsed/Refractory High-Risk Neuroblastoma: A Single Centre Experience
    Olgun, N.
    Cecen, R. E.
    Ince, D.
    Onal, A.
    Baysal, B.
    Akyol, S.
    Ozdogan, O.
    Guleryuz, H.
    Aktas, S.
    Ozer, E.
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S215 - S215
  • [6] Panobinostat Synergistically Enhances the Cytotoxic Effects of Cisplatin, Doxorubicin or Etoposide on High-Risk Neuroblastoma Cells
    Wang, Guan
    Edwards, Holly
    Caldwell, J. Timothy
    Buck, Steven A.
    Qing, William Y.
    Taub, Jeffrey W.
    Ge, Yubin
    Wang, Zhihong
    PLOS ONE, 2013, 8 (09):
  • [7] Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience
    Olgun, Nur
    Cecen, Emre
    Ince, Dilek
    Kizmazoglu, Deniz
    Baysal, Birsen
    Onal, Ayse
    Ozdogan, Ozhan
    Guleryuz, Handan
    Cetingoz, Riza
    Demiral, Ayse
    Olguner, Mustafa
    Celik, Ahmet
    Kamer, Serra
    Ozer, Erdener
    Altun, Zekiye
    Aktas, Safiye
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [8] INADEQUATE RESPONSE TO INDUCTION CHEMOTHERAPY IN CHILDREN WITH HIGH-RISK NEUROBLASTOMA: AN INSTITUTIONAL
    Schrey, D.
    Vaidya, S.
    Levine, D.
    Moreno, L.
    Pearson, A.
    PEDIATRIC BLOOD & CANCER, 2013, 60 : 111 - 111
  • [9] Dinutuximab in adult-onset chemotherapy refractory high-risk neuroblastoma
    Garrovillo, Krystal
    Garrett, John
    Bollin, Kathryn
    Nasraty, Farah
    Sikand, Harminder
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (08) : 2058 - 2065
  • [10] CURETTAGE FOR FOCAL HIGH-RISK SKELETAL NEUROBLASTOMA RESISTANT TO CHEMOTHERAPY AND RADIOTHERAPY
    Salman, Z.
    Kushner, B. H.
    Cheung, N. K. V.
    Basu, E.
    Roberts, S.
    Wolden, S.
    Mora, J.
    Modak, S.
    PEDIATRIC BLOOD & CANCER, 2015, 62 : S334 - S334
12345